Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial

Published:2013-11 Issue:12 Volume:14 Page:1175-1182
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Kang Yoon-Koo,Ryu Min-Hee,Yoo Changhoon,Ryoo Baek-Yeol,Kim Hyun Jin,Lee Jong Jin,Nam Byung-Ho,Ramaiya Nikhil,Jagannathan Jyothi,Demetri George D

Publisher

Elsevier BV

Subject

Oncology

Reference16 articles.

1. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors;Hirota;Science,1998

2. PDGFRA activating mutations in gastrointestinal stromal tumors;Heinrich;Science,2003

3. Gastrointestinal stromal tumours: origin and molecular oncology;Corless;Nat Rev Cancer,2011

4. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors;Demetri;N Engl J Med,2002

5. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT;Blanke;J Clin Oncol,2008

Cited by 158 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect and safety of ripretinib in the treatment of advanced gastrointestinal stromal tumor: A systematic review and meta-analysis;World Journal of Clinical Oncology;2024-08-24

2. Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer;Investigational New Drugs;2024-05-29

3. Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 Plus Imatinib for Advanced Treatment-Refractory Gastrointestinal Stromal Tumors;Clinical Cancer Research;2024-04-25

4. English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology;International Journal of Clinical Oncology;2024-04-13

5. Efficacy and Safety of Ripretinib in Advanced Gastrointestinal Stromal Tumors within an Expanded Access Program: A Cohort Study;Cancers;2024-02-28